|Videos|February 20, 2023
Utilizing CAR T-Cell Therapy in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Author(s)Loretta J. Nastoupil, MD, Marc S. Hoffmann, MD
Wrapping up their discussion, Loretta J. Nastoupil, MD, and Marc S. Hoffman, MD, look at the use of CAR T-cell therapy for patients with mantle cell lymphoma, a rare subtype of non-Hodgkin’s lymphoma.
Advertisement
Episodes in this series
Advertisement
Related to this article
Antibodies directed against TNFR2, a regulator in the TME that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Dostarlimab monotherapy produced a 27% response rate in PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma
Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.
A rituximab biosimilar has been approved by the FDA.
Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.
A post-hoc analysis of LITESPARK-005 found that higher baseline and improved on-treatment QOL scores tracked with lower risk of disease progression and death.
Advertisement
Advertisement
Trending on OncLive
1
Early mRNA Vaccine Data Excite Possibilities of Long-Term PDAC Remissions
2
Expanding Options and Long-Term Data Reshape Frontline and Emerging CLL Treatment Strategies
3
Beyond “I Know It When I See It”: The Murky Reality of Conflict of Interest in Oncology
4
FDA Flashback: GI Cancer Decisions and News From July 2026
5